BJClub – L’importanza della Ricerca in Oncologia

PREMIO MIGLIORE STUDIO INTERNAZIONALE
MASSIMO CRISTOFANILLI

PREMIO MIGLIORE STUDIO ITALIANO
LUCIA DEL MASTRO

PREMIO SPECIALIZZANDO PER MIGLIORE STUDIO
LORENZO GERRATANA

BOARD
ALBERTO BOTTINI
FRANCESCO COGNETTI
PIERFRANCO CONTE
MICHELINO DE LAURENTIIS
LUCIA DEL MASTRO
SABINO DE PLACIDO
LUIGI DOGLIOTTI
DANIELE GENERALI
LUCA GIANNI
GIORGIO MUSTACCHI
PAOLO PRONZATO
FABIO PUGLISI

Relazioni Evento

– GerparNuevo Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer – G. Arpino
– NeoTRIP Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin – G. Bianchini
– EFFECT Evaluation of the efficacy and impact on patient functioning of two doses of nab-paclitaxel in elderly (>65 yrs) breast cancer patients – L. Biganzoli
– Treatment with aromatase inhibitors and markers of cardiovascular disease – E. Blondeaux
– GIM 13 – AMBRA Longitudinal, observational study on the choices of chemotherapy for HER2-negative metastatic breast cancer in the clinical practice – M. Cazzaniga
– Lettura “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double – blind, phase 3 randomised controlled trial” – M. Cristofanilli
– Lettura “Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2X2 factorial, randomised phase 3 trial” – L. Del Mastro
– Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. – M.V. Dieci
– ABRAMYO Phase I-II, multicenter open label study in patients with previously untreated metastatic breast cancer Nab-paclitaxel 100_125 mg/m2 and with LDox 20_25 mg/ m2 will be administered on days 1, 8, 15 of a 28-day cycle until disease progression – A. Fabi
– Pearls from San Antonio 2016 – D. Generali
– In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis – L. Gerratana
– Pearls from ESMO 2016 – M. Giuliano
– Il contributo dell’Associazione AIOM nella ricerca in oncologia – S. Gori
– Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome – G. Griguolo
– The prognostic performance of Adjuvant Online and Nottingham Prognostic Index in young breast cancer patients – M. Lambertini
– Studi Pre-Clinici – P. Vigneri
– Evidenze cliniche di nab-paclitaxel in early disease – M. Zambetti
– tnAcity – M.V. Dieci
– Salute Donna – A. Esposito
– SNAP – A.Gennari
– Europa Donna – Migliuolo
– Evidenze cliniche di nab-paclitaxel in early disease – M. Zambetti